Luca Gianni, MD, on Adding a Checkpoint Inhibitor to Neoadjuvant Regimens in HER2-Positive Breast Cancer

Posted: Tuesday, January 30, 2024

Luca Gianni, MD, of Milan’s Fondazione Michelangelo, discusses some of the clinical issues that stem from findings of the APTneo Michelangelo trial, including whether there are potential benefits to adding a checkpoint inhibitor to standard neoadjuvant regimens for patients with early high-risk or locally advanced HER2-positive breast cancer and how an improvement in pathologic complete response with neoadjuvant treatment (plus adjuvant strategies) might improve overall survival.

---